Toragen, Inc. Announces Appointment of Chief Scientific Officer
08 Feb 2023
Executive Change
SAN DIEGO--(BUSINESS WIRE)--Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus (“HPV”), announced today that it has promoted Rick Lumpkin, PhD to the role of Chief Scientific Officer.
'We are thrilled to have Rick as our Chief Scientific Officer as he brings over 30 years of significant experience in early-stage biotechnology companies and synthetic chemistry. Rick has already made important discoveries at Toragen and has directed the foundational science to swiftly proceed to the clinic.'
Dr. Lumpkin joined Toragen in late 2018 as a consultant and became a fulltime employee in mid-2022. Sandra Coufal, MD, Toragen’s CEO said, “We are thrilled to have Rick as our Chief Scientific Officer as he brings over 30 years of significant experience in early-stage biotechnology companies and synthetic chemistry. Rick has already made important discoveries at Toragen and has directed the foundational science to swiftly proceed to the clinic.”
Prior to Toragen, Dr. Lumpkin served as a founding employee at Global Blood Therapeutics, Portola Pharmaceuticals and Millennium Pharmaceuticals. Additionally, Dr. Lumpkin brings experience from COR Therapeutics, Ribogene, Amylin and Corvas International, Inc.
About Toragen
Toragen, Inc. is targeting the root cause of virally induced cancers. https://toragen.com.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.